Navigation Links
Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
Date:11/1/2007

LONDON, Nov. 1 /PRNewswire/ -- Chiltern, a leading global clinical research organization, is pleased to announce that Diana Hatsis, R.N., B.S.N., C.O.T. will lecture at the JCAHPO annual continuing education program. Diana who designed an ophthalmic surgical instrument, the Hatsis LASIK Irrigation Cannula, worked in ophthalmic practice for several years prior to joining Chiltern as a Clinical Research Associate (CRA). The meeting will take place in New Orleans, Louisiana from November 9 - 13, 2007. The JCAHPO meetings will be located at the Hilton Riverside. Diana will be the lead instructor on three lectures, and co-instructing one of them with her brother, Dr. Alexander Hatsis, M.D., F.A.C.S. Dr. Hatsis was the first surgeon to perform refractive surgery with the Excimer laser on Long Island in 1995.

Monday, Nov. 12 from 11:30 am to 12:25 pm - Session 07M04

Wearing Many Hats: Managing Clinical Trials in an Ophthalmic Private

Practice

Tuesday, Nov, 13 from 10:20 am to 11:15 am - Session 04TU3

LASIK Complications (Lead Instructor: A. Hatsis, MD)

Tuesday, Nov, 13 from 11:30 am to 12:25 pm - Session 04TU4

Sands of the Sahara: A Refractive Emergency (co-instructor A. Hatsis, MD)

Tuesday, Nov, 13 from 1:50 pm to 2:45 pm - Session 07M06

Basic Surgical Assisting

"This will be my eighth year presenting at JCAHPO during AAO's annual meeting, it is always a great honor to be invited and a pleasure to teach and provide continuing education for health professionals in the field of ophthalmology," said Diana Hatsis. "My background in ophthalmology, eye surgeries, working in a private practice and now clinical research allows me to deliver courses with an insight in various aspects of the profession," Diana added.

"One of Chiltern's therapeutic expertise is ophthalmology and we have completed numerous trials, in various indications, in this area. Diana's expertise in the field of ophthalmology is well established and her passion about sharing her knowledge with others is reflected in the number of speaking engagements she has given over the years," said Kathy Zimmermann, Chiltern's Executive Director, Clinical Monitoring, Americas.

About Chiltern:

Established in 1982, Chiltern is a leading global contract research organization with extensive experience of running and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1100 people with 20 offices across the United States, United Kingdom, Germany, France, Italy, Spain, Poland, Czech Republic, Ukraine, India and South Africa. Chiltern provides services including Phase I and laboratory support, Global Clinical Development, Staff Resourcing, Biometrics, Regulatory and Medical Affairs.

For more information contact:

Catherine Lemercier

Chiltern International, Inc.

2111 Palomar Airport Road

Suite 200

Carlsbad

CA 92011

Tel: 1 (760) 707 5025

Fax: 1 (760) 707 5022

Email: Catherine.Lemercier@chiltern.com

Chiltern: Understanding


'/>"/>
SOURCE Chiltern International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bill to Ban Abortion In Indiana Introduced
2. Prince Harry Launches AIDS Charity In Memory Of Princess Diana
3. Over 300 Ill After Eating at Olive Garden, Indianapolis
4. Many Indiana Citizens Do Not Possess Health Insurance Coverage
5. Diana Could Have Been Saved Had She Been Rushed to Hospital
6. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
7. Researchers Present Ways To Reduce The Risk Of Dementia
8. Researchers Present Data Regarding The Efficiency Of Herbs
9. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
10. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
11. Drug Reactions First Present Themselves In The Mouth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
Breaking Medicine Technology: